Related Experiment Video

Updated: Jun 25, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis?

Bernhard Hemmer1, Achim Berthele

  • 1Department of Neurology, Technische Universität München, Munich, Germany. hemmer@lrz.tu-muenchen.de

Nature Clinical Practice. Neurology
|March 6, 2009
PubMed

This commentary discusses a study by van der Voort et al. that tested the diagnostic value of in vivo interferon beta (IFN-beta) bioactivity screening in identifying patients with multiple sclerosis who have developed neutralizing antibodies (NAbs) to IFN-beta therapy--an event that limits the efficacy of the therapy. The in vivo assay used by the authors, which measures expression of the IFN-beta-stimulated gene MxA (MX1) in the peripheral blood, indicated lack of a biological response in 19 of 23 patients with high-titer NAbs following injection of IFN-beta. However, an abnormal response was also observed in 18 of 55 patients who had low-titer NAbs or were NAb negative. The authors concluded that in patients treated with IFN-beta a single postinjection measurement of MxA messenger RNA expression is adequate to determine the IFN-beta bioactivity status. While we believe that in vivo measurement of MxA messenger RNA following IFN-beta injection is a reliable test by which to identify patients with inadequate response to IFN-beta, the capacity of the test to predict treatment failure must be established in a well-designed, prospective trial.

More Related Videos

Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection09:11

Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection

Published on: July 16, 2019

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

Related Concept Videos

Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
Bioavailability: Overview01:13

Bioavailability: Overview

Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...